Out-licensing: Genetic Disorders

Up-to-date access to technology licensing opportunities worldwide.

Out-licensing
Browse

Licensing opportunities

Displaying 11..20 of 36 - per page Previous page Next page
Order by

Farnesyltransferase Inhibitors for Treatment of Laminopathies, Cellular Aging and Atherosclerosis

A possible treatment of laminopathies, cellular aging and aging-related conditions such as HGPS through the use of farnesyltransferase inhibitors (FTIs) and other related compounds More

Improved Method for Analysis of Microarray and Other Multidimensional Data

Improved accuracy in pattern recognition of clustered multidimensional data More

Novel Means of Greatly Extending Lifespan and Resistance to Oxidative Stress (07-30)

Increase in lifespan More

Overexpressed in Werner's Syndrome Fibroblasts More

Gene Therapy by Administration of Genetically Engineered CD34+ Obtained by Cord Blood

A method of providing a therapeutic effect in human patients by administering to the patient CD34+ cells obtained from umbilical cord blood. More

Diagnosis and Prognosis of Fabry Disease by Detecting Neuronal Apoptosis Inhibitor Protein (NAIP) Expression

Rapid diagnostic assay to identify individuals with Fabry disease and an effective mechanism of evaluating enzyme replacement therapy More

Mammalian β-Galactosidase Reporter Genes

Mammalian lactase gene constructs for use as autologous mammalian lactase gene constructs for use as autologous β-galactosidase reporter genes More

PharmiGene Inc.: Technology associated with the PG 1502 DNA Detection Kit and the PG1502 FastGel Kit

Technology associated with PharmiGene's PG 1502 DNA Detection Kit and the PG1502 FastGel Kit, kits to determine the risk of Carbamazepine-induced SJS/TEN adverse drug reaction (ADR). More

PharmiGene Inc.:Technology associated with the PG 5801 DNA Detection Kit and the PG 5801 FastGel Kit

Technology associated with PharmiGene's PG 5801 DNA Detection Kit and the PG 5801 FastGel Kit, kits to determine the risk of Allopurinol-induced severe cutaneous adverse reaction (SCAR). More

PharmiGene Inc.: Technology associated with the Warfarin Dose Prediction Kit

Technology associated with PharmiGene's Warfarin Dose Prediction Kit, a kit to determine the appropriate Warfarin dosage administration based on the presence of the VKORC1-1639 and CYP2C9 genes. More

Displaying 11..20 of 36 - per page Previous page Next page
Order by

Your selection

Therapeutic target: Genetic disorders del

Browse By

Industry sector: Animal health; Biotechnology; Diagnostic; Drug delivery; Drug discovery; Medical device; Pharmaceutical; Research tools
Therapeutic target: Birth defects; Blood clotting disorders; Fabry's disease; Gaucher's disease; Genetic disorder (other); Hunter's syndrome; Huntington's disease; Kawasaki disease; Klinefelter's syndrome; Phenylketonuria; Severe combined immunodeficiency; Turner's syndrome
Development phase: Early Stage; Preclinical; Phase I; Phase I/II; Phase II; Phase III; Phase III/IV; Preregistration; Registered

Products:	Partnering Search	Company Profiling	Deal Negotiation	PL Intelligence	Reports	Comparision
In-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Out-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Companies:	Profiled companies	Industry Sector	Therapeutic Target	Geographic Location	Search	Add your company
Reports:	Biotechnology	Business Development	Management	Market & Sales	Medical Devices	Pharmaceuticals
Jobs:	Pharmaceutical jobs	Browse jobs	Search for jobs	Create your CV	Employer profiles	Post your jobs
Forums:	Talk to an expert	Industry Gossip	Business Development	What's new	Reports	Services
News:	Deals & Alliances	Development	Financial Results	Financings	Intellectual Property	Regulatory
Events:	Pharma events	Calendar	Organizers	Featured events	Search
Articles:	Business Development	Technologies	Events	Legal and regulatory	Therapeutic
Deals:	Industry Sector	Therapeutic Target	Deals Date	Search	Reports	Press releases
About us:	Our Audience	Case Studies	Newsletter	Careers	FAQ	Contact us